Moderate riskFDA DrugClass II

Zydus mirabegron tablets recalled for N-nitroso impurity

Zydus Pharmaceuticals is recalling one lot of Mirabegron Extended-Release 25 mg tablets due to higher-than-acceptable levels of N-Nitroso Mirabegron impurity. This impurity can potentially increase long-term health risks with continued use. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Zydus recalls

What to do

  1. Check if your Mirabegron bottle has lot number E408618 (expiration 11/30/2026).
  2. Contact your pharmacy or doctor if you have this lot — do not stop taking the medication without guidance.
  3. Your pharmacy can provide an unaffected replacement or alternative medication.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1159-3.
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Illnesses reported
None reported
Manufactured in
73 Route 31 N, Pennington, NJ, United States
Classification
Class II
Recall number
D-0745-2026

In the FDA's words

Description
Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1159-3. CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity. Lot # E408618, Expiry: 11/30/2026, NDC #: 70710-1159-3 Distribution: Nationwide in the USA
Hazard
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.

More from Zydus

See all

Related topics

Industrial chemicalsDrugsSold nationwideMore from FDA Drug